Search Results - "Shen, Weina"

Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial by Chen, Shasha, Shen, Weina, Liu, Yuhuan, Dong, Qiang, Shi, Yongquan

“…With the development of traditional Chinese medicine research, berberine has shown good efficacy and safety in the eradication of Helicobacter pylori (H…”
Get full text

Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor by Ji, Dongmei, Jiang, Shiyu, Zhang, Qunling, Wang, Y. Ken, Zhang, Jian, Shen, Weina, Li, Wenhua, Liu, Rujiao, Wang, Jessica, Mavis, Cory, Gu, Juan J., Hu, Xichun

“…Serologic biomarker to predict clinical outcome is needed for immune checkpoint inhibitors (ICIs). We evaluated soluble intercellular adhesion molecules‐1…”
Get full text

Prognostic prediction of lung adenocarcinoma by integrative analysis of RHOH expression and methylation by Kuang, Muyu, Zhou, Zhenhua, Lu, Zhongyuan, Shen, Weina, Ge, Haiyan, Tao, Xiaoting, Zhao, Yue, Zhuge, Lingdun, Sun, Yihua, Ji, Dongmei, Zhang, Huibiao

“…Background and objective The development of epigenetics holds great promise for diagnosis and treatment of lung adenocarcinoma (LUAD). The purpose of this work…”
Get full text

A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers by Zhang, Jian, Yang, Nong, Ji, Dongmei, Shen, Weina, Li, Wenhua, Han, Rubing, Wang, Ning, Tao, Haoxun, Chapman, Sonya C., Sykes, Amanda K., Zhang, Wanli, Hu, Xichun

“…Background Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, is approved in combination with endocrine therapy or as monotherapy for hormone…”
Get full text

Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases by Li, Xiaoyang, Shen, Weina, Cao, Junning, Wang, Jianmin, Chen, Fangyuan, Wang, Chun, Zou, Shanhua, Shen, Boyong, Zhao, Ren, Li, Junmin, Shen, Zhixiang

“…Gastrointestinal diffuse large B cell lymphoma (DLBCL) is a common subtype of extranodal lymphoma. There has been uncertainty about the clinical efficacy of…”
Get full text

Phase I Trial of a Novel Anti-HER2 Antibody-drug Conjugate, ARX788, for the Treatment of HER2-positive Metastatic Breast Cancer by Zhang, Jian, Ji, Dongmei, Shen, Weina, Xiao, Qin, Gu, Yajia, O'Shaughnessy, Joyce, Hu, Xichun

“…ARX788 is a novel antibody-drug conjugate (ADC) comprised of an anti-HER2 monoclonal antibody and a potent tubulin inhibitor payload AS269 that is…”
Get full text

Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study by Ji, Dongmei, Shen, Weina, Li, Ting, Wang, Huan, Bai, Jianling, Cao, Junning, Hu, Xichun

“…This phase 1b study aimed to evaluate the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), pharmacokinetics, and preliminary efficacy of HR070803, a…”
Get full text

A phase II study to evaluate the efficacy and safety of camrelizumab plus famitinib in advanced or metastatic thyroid cancer by Ji, Dongmei, Shen, Weina, Kuang, Muyu, Liu, Ying, Li, Huajun, Wang, Yu, Ji, Qinghai

“…6085 Background: Many studies have confirmed that the combination with anti-vascular drugs can significantly improve the efficacy of anti-PD-1/PD-L1 inhibitor…”
Get full text

First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study by Zhang, Jian, Ji, Dongmei, Cai, Li, Yao, Herui, Yan, Min, Wang, Xiaojia, Shen, Weina, Du, Yiqun, Pang, Hui, Lai, Xiuping, Zeng, Huiai, Huang, Jian, Sun, Yan, Peng, Xinxin, Xu, Junfang, Yang, Jing, Yang, Fei, Xu, Ting, Hu, Xichun

“…KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes. This first-in-human phase I study evaluated the…”
Get full text

Construction and Validation of a Gastric Cancer Diagnostic Model based on Blood Groups and Tumor Markers by Liu, Yuhuan, Chen, Shasha, Shen, Weina, Qu, Xiaodong, Li, Songbo, Shi, Yongquan

“…The aim of this study is to explore the value of combined detection of ABO blood group and tumor markers in the diagnosis of gastric cancer. A total of 3650…”
Get full text

Abstract 3919: GSK458, a novel oral dual PI3K/mTOR Inhibitor, is effective in preclinical model of T-cell lymphoma alone and in combination therapies by Gu, Juan J., yang, Lianjuan, He, Jing, Shen, Weina, Mavis, Cory, Hernandez-Ilizaliturri, Francisco

“…Abstract Purpose: Despite T cell lymphoma (TCL) responses well at the initial chemotherapy, the outcome of TCL remains poor when it becomes systematic disease…”
Get full text

Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial by Cao, Junning, Guo, Hongqian, Ji, Dongmei, Shen, Weina, Zhang, Shun, Hsieh, Chih-Yi, Xiong Cai, Sui, Edward Tian, Ye, Xu, Cong, Zhang, Pin, Xu, Binghe

“…Senaparib, a novel poly(ADP-ribose) polymerase 1/2 inhibitor, demonstrated antitumor activity in preclinical studies. This phase I, first-in-human,…”
Get full text

A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer by Ji, Dongmei, Song, Lijie, Cheng, Ying, Shen, Weina, Kuang, Muyu, Chen, Jiaying, Yang, Minjie, Cui, Hongxia, Zhou, Jinghong, Shi, Haiyan, Tan, Panfeng, Fan, Songhua, Shi, Michael, Su, Weiguo, Ji, Qinghai

“…6089 Background: For patients (pts) with radioactive iodine–refractory differentiated thyroid cancer (RAIR-DTC), there presents a considerable therapeutic…”
Get full text

Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial by Zhang, Panpan, Shi, Si, Xu, Jianming, Chen, Zhendong, Song, Lijie, Zhang, Xing, Cheng, Ying, Zhang, Yanqiao, Ye, Feng, Li, Zhiping, Yin, Fei, Ji, Dongmei, Gao, Heli, Li, Yi, Chen, Wei, Yang, Minjie, Weng, Desheng, Wu, Chunjiao, Ma, Yue, Sheng, Wang, Zhao, Yaqin, Yin, Xiaolei, Shen, Weina, Su, Weiguo, Shi, Michael, Fan, Songhua, Tan, Panfeng, Xu, Qian, Lu, Ming, Shen, Lin

“…The programmed death 1 inhibitor toripalimab plus the angio-immuno kinase inhibitor surufatinib revealed a tolerable safety profile and preliminary efficacy in…”
Get full text

Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas by Cao, Junning, Li, Zhiming, Zhou, Jianfeng, Ji, Dongmei, Shen, Weina, Sun, Peng, Wang, Yu, Li, Dengju, Hong, Zhenya, Wang, Gaoxiang, Duan, Xianlin, Yu, Chen, Cai, Yu, Su, Weiguo

“…Introduction HMPL-689 is a potent and highly selective small molecule inhibitor of phosphoinositide 3-kinase-delta (PI3Kδ). Despite available agents targeting…”
Get full text

Abstract PD8-04: Safety and anti-tumor activity of ARX788 in HER2-positive metastatic breast cancer patients whose disease is resistant/refractory to HER2 targeted agents (trastuzumab, ADCs, TKIs, and bispecific antibodies): ACE-Breast-01 trial results by Zhang, Jiang, Ji, Dongmei, Shen, Weina, Xiao, Qin, Gu, Yajia, O’Shaughnessy, Joyce, Xia, Gang, Ji, Yanping, Xiong, Gaozhun, Li, Matt, Xu, Dong, Cartmell, Robert, Song, Cynthia, Yan, Jinchun, Hu, Xichun

“…Abstract Introduction: HER2 is overexpressed on 15-20% of breast cancers and is a clinically important cancer driver. In spite of the HER2 targeted therapy’s…”
Get full text

Abstract P2-13-10: First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study by Zhang, Jian, Ji, Dongmei, Cai, Li, Yao, Herui, Yan, Min, Wang, Xiaojia, Shen, Weina, Du, Yiqun, Pang, Hui, Lai, Xiuping, Zeng, Huiai, Huang, Jian, Sun, Yan, Peng, Xinxin, Xu, Junfang, Yang, Jing, Yang, Fei, Xu, Ting, Hu, Xichun

“…Abstract PURPOSE KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes. This firstinhuman Phase I study evaluated the…”
Get full text

Abstract CT164: A phase 1 study of abemaciclib in Chinese patients with advanced and/or metastatic cancers by Hu, Xichun, Yang, Nong, Zhang, Jian, Zhou, Chunhua, Ji, Dongmei, Shen, Weina, Li, Wenhua, Han, Rubing, Lu, Yi, Chapman, Sonya C.

“…Abstract Background: Abemaciclib, a cyclin-dependent kinase 4 & 6 inhibitor, is approved in combination with endocrine therapy or as a single agent for…”
Get full text

Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer by Ji, Dongmei, Zhang, Jian, Shen, Weina, Du, Yiqun, Xu, June, Yang, Jing, Luo, Xin, Kong, Paul, Yang, Fei, Hu, Xi-Chun

“…Abstract only 1041 Background: KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes, the same domains as trastuzumab…”
Get full text

GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy by Gu, Juan, Yang, Lianjuan, Gaughan, Dennis C, He, Ling, Shen, Weina, Mavis, Cory, Hernandez-Ilizaliturri, Francisco J.

“…Introduction: T-cell lymphoma (TCL) accounts approximately 15% of all Non-Hodgkin's lymphoma cases. TCL are often divided into either systemic or cutaneous TCL…”
Get full text